Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Researchers develop new diagnostic marker for early detection of acute kidney injury

Abbott Laboratories Medical Diagnostics Products : 30 July, 2008  (Company News)
Researchers have developed a new diagnostic marker, called urine NGAL, for early detection of acute kidney injury (AKI) in hospitalised patients can distinguish AKI from other forms of kidney dysfunction and prevent kidney failure.
A paper describing the marker was presented at the American Association for Clinical Chemistry (AACC) annual meeting.

The research was presented by Prasad Devarajan, MD, director of nephrology and hypertension, Cincinnati Children's Hospital Medical Center, at a scientific workshop hosted by Abbott.

AKI is a common and potentially devastating illness in hospitalised patients. Onset is rapid and can result from trauma, sepsis or administration of medications toxic to the kidneys. AKI can also present following cardiothoracic surgery or as a complication of diabetes and other chronic conditions. AKI quickly reduces the ability of the kidneys to filter waste and leads to renal failure. Many patients with a severe form of AKI face extensive time on dialysis. The mortality rate for patients with AKI ranges up to more than 80 percent in post-operative settings, according to a study reported recently in the Annals of Internal Medicine.

'Unfortunately, the current testing procedure for AKI - a blood test to measure the ability of the kidneys to filter creatinine into the urine is unable to identify the problem in the first 48 hours when time is critical for preventing kidney failure,' said Dr Devarajan. 'The incidence of this common complication has risen by 11 percent in recent years, and we need better ways to diagnose and treat the condition and lower the risk of death or needing dialysis,'.

Devarajan reported today the results of clinical studies conducted for a new diagnostic Biomarker for acute AKI, called urine NGAL (neutrophil gelatinase-associated lipocalin). The protein is produced by the kidney tubules and appears in urine just two to four hours following AKI, up to 46 hours sooner than biomarkers detected by current testing methods.

'The urine NGAL marker has the potential to represent a major advance in identifying patients at risk for developing AKI after surgery or trauma and in other situations commonly seen in critically ill patients,' Devarajan said.

Devarajan noted that delayed diagnosis of AKI with currently-used creatinine tests may prevent physicians from using hydration or blood pressure support in a timely manner to lower the risk for patient harm.

The costs of AKI are a substantial $10 billion a year, mainly from lengthy hospital stays and expensive interventions, according to Chirag Parikh, MD, PhD, associate professor of medicine, Yale University Medical School. 'Serum creatinine testing is inadequate. It is a non-specific marker that delays diagnosis of AKI. New biomarkers are needed to stimulate testing of new therapies and significantly decrease the mortality in AKI and costs associated with it,' he said.

In his research, Devarajan analyzed urine samples from children with congenital heart defects who had cardiopulmonary bypass surgery. The procedure is a major risk factor for AKI. Half of the children developed AKI, based on results of creatinine tests reported two to three days after surgery.

However, their NGAL levels began to increase within a few hours. 'Rises in urine NGAL levels at two hours identified 90 percent of children who later developed AKI. Urine NGAL, therefore, was highly predictive of AKI risk, and we found those with higher levels were more likely to die or need dialysis,' Devarajan said. He added that these findings have been confirmed in adult populations.

About 65 percent of patients with the highest increase in urine NGAL will require immediate care by a nephrologist and a third will go on dialysis.

'Clinically, there is no comparison since NGAL provides specific and rapid diagnosis of AKI while creatinine blood tests are not able to distinguish AKI from chronic kidney disease,' Devarajan said.

'From the single drop of urine, we obtain essential information when time is critical to help prevent kidney failure and save lives. With close monitoring, the early information provided by the NGAL test could make treatments more effective if started at the beginning of AKI.'

Devarajan presented his findings during a symposium at AACC titled Translational Medicine and the Clinical Laboratory: Emerging Biomarkers for Acute Kidney Injury. The marker has been the subject of recent articles published in Lancet, Annals of Internal Medicine and the Clinical Journal of the American Society of Nephrology. Devarajan's research was supported, in part, by a restricted research grant from Abbott.

Abbott is developing a urine NGAL test and has initiated international clinical trials.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo